Regorafenib

What is Regorafenib?

Regorafenib is an oral multikinase inhibitor medication primarily used in the treatment of certain advanced cancers. Marketed as Stivarga, it belongs to a class of drugs that work by blocking multiple enzymes (kinases) involved in cancer cell growth, proliferation, and the formation of new blood vessels that feed tumors. Approved for several challenging cancer types, Regorafenib offers a crucial treatment option for patients who have exhausted other therapies or whose disease has progressed, helping to slow progression and improve outcomes.

How Does it Work?

The therapeutic efficacy of Regorafenib stems from its ability to inhibit a wide range of protein kinases critical for oncogenesis, angiogenesis, and maintenance of the tumor microenvironment. Specifically, Regorafenib targets VEGFR1, VEGFR2, VEGFR3, TIE2, RAF, BRAF, KIT, RET, and PDGFR. By inhibiting these pathways, Regorafenib: disrupts angiogenesis by starving tumors; blocks oncogenic signaling, interfering with uncontrolled growth; and modulates the tumor microenvironment, further impeding tumor growth. This multi-targeted approach makes it effective against various cancer types.

Medical Uses

Regorafenib is approved for the treatment of specific advanced cancers:

• Metastatic Colorectal Cancer (mCRC)

  Indicated for patients with metastatic colorectal cancer previously treated with, or unsuitable for, standard chemotherapy regimens and targeted therapies (anti-VEGF, anti-EGFR if RAS wild-type). Regorafenib provides a crucial oral option to extend survival.

• Gastrointestinal Stromal Tumors (GIST)

  Approved for unresectable or gastrointestinal stromal tumors that have progressed or are intolerant to prior treatment with imatinib and sunitinib. It addresses an unmet need for patients with advanced GIST resistant to standard tyrosine kinase inhibitors.

• Hepatocellular Carcinoma (HCC)

  Indicated for patients with hepatocellular carcinoma previously treated with sorafenib. Regorafenib offers a second-line systemic treatment option, demonstrating improved overall survival.

Dosage

The typical dose of Regorafenib is 160 mg (four 40 mg tablets) orally once daily for 21 days, followed by 7 days off, completing a 28-day cycle. Tablets should be taken at the same time each day after a light, low-fat meal. Dosage adjustments may be necessary based on individual patient tolerance and the occurrence of adverse reactions. Adherence to the prescribed regimen and reporting any side effects to a healthcare provider are crucial.

Side Effects

As with most potent cancer therapies, Regorafenib can cause a range of side effects. Common adverse reactions include: hand-foot skin reaction (palmar-plantar erythrodysesthesia), fatigue, diarrhea, decreased appetite, hypertension (high blood pressure), dysphonia (hoarseness), infections, abdominal pain, rash, and liver enzyme elevations. More serious, though less common, effects can include severe hepatotoxicity, hemorrhage (bleeding), gastrointestinal perforation, dermatological toxicities (e.g., severe rash, skin exfoliation), cardiac ischemia or infarction, and reversible posterior leukoencephalopathy syndrome (RPLS). Patients are closely monitored by their healthcare team for effective management.

Drug Interactions

Regorafenib is metabolized primarily by cytochrome P450 3A4 (CYP3A4) and is a P-glycoprotein (P-gp) substrate. Co-administration with other drugs can significantly alter its plasma concentrations: strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice) can increase Regorafenib exposure, potentially leading to increased toxicity; dose reduction may be necessary. Strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, St. John's Wort) can decrease Regorafenib exposure, potentially reducing its efficacy; avoid co-administration if possible. While a P-gp substrate, its clinical significance is considered less pronounced than for CYP3A4. Inform your doctor about all medications, supplements, and herbal products you are taking to avoid potential harmful interactions.

Frequently Asked Questions (FAQ)

What is the brand name for Regorafenib?

The brand name for Regorafenib is Stivarga.

How often is Regorafenib taken?

It is typically taken once daily for 21 days, followed by 7 days off, completing a 28-day cycle.

What type of drug is Regorafenib?

It is a multikinase inhibitor, a targeted therapy that blocks multiple enzymes involved in cancer growth.

What cancers does Regorafenib treat?

It is used to treat metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma.

Can Regorafenib cure cancer?

While Regorafenib can significantly slow cancer progression and extend life, it is generally not considered a cure for the advanced cancers it treats. It aims to control the disease and improve quality of life.

Products containing Regorafenib are available through trusted online pharmacies. You can browse Regorafenib-based medications at ShipperVIP or Medicenter.

Summary

Regorafenib, known commercially as Stivarga, represents a vital advance in the treatment of several difficult-to-treat cancers, including metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma. As a multikinase inhibitor, it targets multiple pathways crucial for tumor growth and angiogenesis, offering a mechanism of action that addresses resistance to other therapies. While its use comes with potential side effects and requires careful management of drug interactions, Regorafenib provides a valuable option for patients seeking to extend their lives and manage their disease progression.